| Biomarker ID | 844 |
| PMID | 22298030 |
| Year | 2012 |
| Biomarker | let-7c + let-7e+miR30c+ miR-622+ miR1285 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Differentially expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(let-7c):- MicroRNAs in cancer; tRNA processing in the mitochondrion; rRNA processing in the mitochondrion; Gene expression (Transcription); DNA-binding transcription factor activity Pathways Include(let-7e):- DNA-binding transcription factor activity; DNA-binding transcription factor activity, RNA polymerase II-specific; nuclear lumen; chromatin; nuclear chromosome Pathways Include(miR-30c):- regulation of transcription by RNA polymerase II; Gene expression (Transcription); cellular protein modification process; Protein modification process; cellular metabolic process Pathways Include(miR-622):- DNA-binding transcription factor activity; positive regulation of gene expression; Pathways in cancer;regulation of cellular component organization; positive regulation of transcription, DNA-templated Pathways Include(miR1285):- Golgi apparatus; regulation of Ras protein signal transduction; regulation of small GTPase mediated signal transduction; synapse |
| Experiment | Prostate Cancer Vs Healthy Men |
| Type of Biomarker | Diagnostic |
| Cohort | Training set: 25 patients with prostate cancer, 17 with Benign prostatic hyperplasia. Validation Set: 80 CaP, 44 BPH, and 54 healthy controls |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.860 (95% CI: 0.795– 0.925) |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Training Set: Microarrays, Validation set; qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | let-7c, let-7e, miR30c, miR-622, miR1285 |